1. Theme 9 Clinical Trials and Trial Design.
- Author
-
Ghandour, S., Avan, A., Benedetti, A., Matte, G., Mann, K., Gaskin, S. J., Severt, L., Heckman, L., Paredes, E., Mittal, N., Abeliovich, A., Berlowitz, D., Rowe, D., Howard, M. E., Piper, A., Braat, S., Singh, B., Souza, T. V., Lannin, N., and McLean, A.
- Subjects
MEDICAL personnel ,MACROPHAGE migration inhibitory factor ,AMYOTROPHIC lateral sclerosis ,CLINICAL trials monitoring ,MOTOR neuron diseases - Abstract
The article explores clinical trials and trial design for potential treatments for Amyotrophic Lateral Sclerosis (ALS), including studies on copper exposure, gene therapies, and microbiome ecosystem therapy. The research aims to improve disease progression, survival rates, and quality of life for ALS patients, with a focus on safety and efficacy. One study evaluated the safety and tolerability of trimetazidine in ALS patients, showing promising results in reducing oxidative stress markers and resting energy expenditure. The study was conducted in Australia and the Netherlands and is registered under ClinicalTrial.gov number NCT04788745 and EudraCT number 2020-005018-17. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF